

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**

**叮噹健康科技集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 09886)**

## **POSITIVE PROFIT ALERT – NARROWING OF LOSS**

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025 (the “**FY2025**”), the net loss for FY2025 is expected to narrow significantly by more than 80% compared to the net loss of approximately RMB380.0 million for the year ended December 31, 2024 (the “**FY2024**”). Such improvement was primarily attributable to the following factors:

First, an impairment loss of goodwill of approximately RMB198.9 million and an impairment loss of other intangible assets of approximately RMB6.8 million were recognized in FY2024, and the relevant impairment amount is expected to decrease significantly in FY2025.

Second, the Group has continued to optimize its urban layout strategy, focusing on and deepening its presence in core first-tier cities represented by Beijing, Shanghai and Shenzhen. It has actively expanded and densified the local smart pharmacy networks, effectively enhanced operational efficiency and driven steady growth of the overall business.

Third, in terms of merchandise, the Group has further strengthened its supply chain service capabilities, continuously optimized the product sales mix and increased the proportion of high gross profit product categories, thereby significantly improving the overall operational efficiency and profitability.

Benefiting from multiple favorable factors, the Group also expects to record an adjusted net profit (Note: a non-IFRS measure) of not less than approximately RMB5 million for FY2025, achieving a turnaround from loss to profit compared to the adjusted net loss of approximately RMB57.2 million for FY2024.

**Note:** The adjusted net profit/(loss) (non-IFRS measure) is provided by the Company as an additional financial indicator to supplement the consolidated financial statements prepared in accordance with IFRS. This measure is not required by, nor presented in accordance with, IFRS. According to the Company's latest business operations and financial condition, the adjusted net profit (non-IFRS measure) for FY2025 is calculated by taking the net loss for FY2025 and adding back impairment of goodwill (if any) and other intangible assets (net of income tax effects) (if any), amortization of other intangible assets arising from acquisitions (net of income tax effects) and share-based payments expenses. The Company believes that the adjusted net profit/(loss) (non-IFRS measure) provides useful information to assist the Company's management in understanding and evaluating the consolidated results of operations. However, the presentation of the adjusted net profit/(loss) (non-IFRS measure) may not be comparable to other similarly titled indicators presented. The use of adjusted net profit/(loss) (non-IFRS measure) as an analytical tool has limitations, and Shareholders and potential investors should not consider it in isolation from, or as a substitute for analysis of, the results of operations or financial conditions of the Company as reported under IFRS.

The Company is still in the process of finalizing the annual results of the Group for FY2025. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available, and is not audited or reviewed by the auditor or the audit committee of the Company and may differ from the actual annual results of the Group for FY2025. Shareholders and potential investors of the Company should refer to and carefully read the annual results announcement of the Company for FY2025, which is expected to be published in March 2026.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**  
**YANG WENLONG**  
*Chairman*

Hong Kong, February 16, 2026

*As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. YANG Yibin, Mr. XU Ning, Mr. YU Qinglong and Mr. MENG Fanzhou, the non-executive Director is Ms. LI Chuheng, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.*